
Abbott lowers 2026 outlook amid demand headwinds; spin-off may boost growth and margins.
Abbott Laboratories has lowered its full-year 2026 guidance following weaker-than-expected demand in its EP/CGM segments during the fourth quarter. The company plans a nutrition business spin-off, which could unlock growth in its MedTech, Diagnostic,...




